The estimated Net Worth of Warren D Cooper is at least $98.6 Thousand dollars as of 13 June 2023. Warren Cooper owns over 115 units of Zynerba Pharmaceuticals Inc stock worth over $98,511 and over the last 9 years he sold ZYNE stock worth over $81. In addition, he makes $0 as Lead Independent Director at Zynerba Pharmaceuticals Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Warren Cooper ZYNE stock SEC Form 4 insiders trading
Warren has made over 2 trades of the Zynerba Pharmaceuticals Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 115 units of ZYNE stock worth $40 on 13 June 2023.
The largest trade he's ever made was selling 115 units of Zynerba Pharmaceuticals Inc stock on 13 June 2023 worth over $40. On average, Warren trades about 14 units every 33 days since 2015. As of 13 June 2023 he still owns at least 75,778 units of Zynerba Pharmaceuticals Inc stock.
You can see the complete history of Warren Cooper stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Warren Cooper biography
Dr. Warren D. Cooper MB, BS, BSc, serves as Lead Independent Director of the Company. Dr. Cooper is a U.K.-trained physician with more than 35 years of experience in the global pharmaceutical industry. Since January 2017, Dr. Cooper has served as chief medical officer and a partner of Healthcare Royalty Partners, a healthcare investment firm. Prior to joining Healthcare Royalty Partners in January 2017, Dr. Cooper served as the president of Coalescence Inc., a healthcare and pharmaceutical development consultancy, where he held various positions since 1999. Dr. Cooper was the chief executive officer of Prism Pharmaceuticals, Inc., a venture-backed, specialty pharmaceutical company that he led from inception in September 2004 until the sale of the company to Baxter International in May 2011. His career in the pharmaceutical industry began with Merck, Sharp and Dohme and spanned 12 years, initially as a clinical research physician in the United Kingdom, then as head of European and, subsequently, Worldwide Clinical Research Operations for Merck Research Laboratories across all therapeutic areas. Moving to AstraMerck (now AstraZeneca PLC), or AstraZeneca, in a broad clinical development role, he eventually led that company's cardiovascular business division, a role with full business lifecycle leadership from in-licensing through development, to P&L responsibility for sales and marketing. Dr. Cooper is a member of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom. He has previously served on the boards of directors of Nutrition 21, Inc., Nuron Biotech Inc., Cardiorentis AG and the World Affairs Council of Philadelphia. Dr. Cooper holds a B.Sc. in Physiology, an M.B. and a B.S., each from the London Hospital, University of London. With more than 35 years of experience in the global pharmaceutical industry, Dr. Cooper brings valuable expertise in pharmaceutical company leadership and clinical pharmaceutical research to our Board.
How old is Warren Cooper?
Warren Cooper is 67, he's been the Lead Independent Director of Zynerba Pharmaceuticals Inc since 2015. There are 1 older and 13 younger executives at Zynerba Pharmaceuticals Inc. The oldest executive at Zynerba Pharmaceuticals Inc is Daniel Kisner, 72, who is the Independent Director.
What's Warren Cooper's mailing address?
Warren's mailing address filed with the SEC is C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON, PA, 19333.
Insiders trading at Zynerba Pharmaceuticals Inc
Over the last 9 years, insiders at Zynerba Pharmaceuticals Inc have traded over $154,101 worth of Zynerba Pharmaceuticals Inc stock and bought 224,703 units worth $2,383,877 . The most active insiders traders include John P. Butler, William J Federici, and Michael Rapp. On average, Zynerba Pharmaceuticals Inc executives and independent directors trade stock every 69 days with the average trade being worth of $12,515. The most recent stock trade was executed by Terri B Sebree on 12 September 2023, trading 12,401 units of ZYNE stock currently worth $16,493.
What does Zynerba Pharmaceuticals Inc do?
at zynerba pharmaceuticals (nasdaq: zyne), we are dedicated to developing next-generation synthetic cannabinoid therapeutics for transdermal delivery for patients with significant unmet medical needs. our mission is to improve the lives of patients battling severe health conditions including refractory epilepsy, osteoarthritis, fragile x syndrome, fibromyalgia and peripheral neuropathic pain through these therapeutics. our development pipeline includes patent-protected synthetic transdermal cannabinoid products, cbd gel – zyn002 and thc pro-drug patch – zyn001, which we believe will provide new treatment options for patients as well as additional treatment options for patients not currently receiving adequate relief or otherwise experiencing intolerable side effects from current treatment regimes.
What does Zynerba Pharmaceuticals Inc's logo look like?
Complete history of Warren Cooper stock trades at Zynerba Pharmaceuticals Inc
Zynerba Pharmaceuticals Inc executives and stock owners
Zynerba Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Armando Anido,
Chairman of the Board, Chief Executive Officer -
Terri Sebree,
President -
Armando Anido MBA,
Chairman & CEO -
James Fickenscher,
Chief Financial Officer, Vice President - Corporate Development -
Terri B. Sebree,
Pres -
James E. Fickenscher,
CFO, VP of Corp. Devel. & Treasurer -
Suzanne Hanlon,
Vice President, General Counsel, Secretary -
William Roberts,
Vice President, Investor Relations and Corporate Communications -
Pamela Stephenson,
Independent Director -
Kenneth Moch,
Independent Director -
Daniel Kisner,
Independent Director -
William Federici,
Independent Director -
John Butler,
Independent Director -
Warren Cooper,
Lead Independent Director -
Brian Rosenberger,
Vice President - Commercial and Business Development -
Joseph Apostolico,
VP of HR -
Suzanne M. Hanlon,
Sec., VP & Gen. Counsel -
Dr. Joseph Palumbo,
Chief Medical Officer -
Thomas L Harrison,
Director -
Michael Rapp,
10% owner -
Cynthia Ann Rask,
Director -
Albert P Parker,
Chief Legal Officer -
Richard A Baron,
Chief Financial Officer -
Kenneth T Jones,
See Remarks